Interleukin-1receptor antagonist in hypertensive patients with varying degrees of cardiovascular complications


Purpose. The aim of this study was to evaluate the concentration of interleukin-1 receptor antagonist in hypertensive patients with varying degrees of cardiovascular complications. Materials and methods. In 161 patients with I, II grade arterial hypertension aged 35 to 56 years, divided into 3 groups depending on the risk of development of cardiovascular complications were gone examination including echocardiography, ultrasound dopplerography of brachiocephalic vessels , daily blood pressure monitoring, lipid spectrum, glucose level, creatinine level, glomerular filtration rate and IL-1(ra) concentrations in blood serum. Results. In hypertensive patients with moderate cardiovascular risk the severity of inflammatory process depends on the presence of abdominal obesity. In hypertensive patients with high risk of cardiovascular complications direct correlation between IL-1(ra) and intima-media thickening and inverse correlation between IL-1(ra) concentration and GFR was found, it can indicate the association of inflammatory process, renal damage and structural changes of vascular wall which can play a crucial role in pathogenesis of arterial hypertension and development of organ damage.

About the authors

E V Kiseleva

E V Kiseleva


  1. Харченко В. И., Какорина Е. П., Корякин М. В. и др. Смертность от основных болезней системы кровообращения в России (Аналитический обзор официальных данных Госкомстата, Минздрава России, ВОЗ и экспертных оценок по проблеме) //Российский кардиологический журнал. - 2005. - № 2. - С. 5-7
  2. Van Lerberghe W., Evans T., Rasanathan K., Mechbal A. 2008. The World Health Report 2008: Primary Health Care-Now More Than Ever Geneva: World Health Organization
  3. Grundy S.M., Cheeman J.I., Merz C.N. et al "Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines." Circ. 2004 110, 227-239
  4. Packard R.R., Libby P. "Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction." Clin Chem. 2008 54(1) . 24-38
  5. Ройтберг Г.Е., Струтынский А.В. Внутренние болезни. Сердечно-сосудистая система. М: Бином-пресс.2007
  6. A.C.T.M. Peeters, M.G. Netea, M.C.H. Janssen, B.J. Kullberg, J.W.M van der Meer, and T.Thien, "Pro-inflammatory cytokines in patients with essential hypertension", European Journal of Clinical Investigation. - 2001. 31. (1)31 - 36
  7. Fabrizio Montecucco, Aldo Pende ,Alessandra Quercioli , François Mach "Inflammation in the pathophysiology of essential hypertension" JNEPHROL 2011; 24(01): 23- 34
  8. M. Vanhala, H.Kautiainen, E. Kumpusalo, "Proinflammmation and Hypertension: a population-based study", Mediators of inflammation. - 2008. - Vol. 2008, Article ID: 619704
  9. William F. Fearon and Douglas T. Fearon "Inflammation and Cardiovascular Disease: Role of the Interleukin-1 Receptor Antagonist" Circulation. 2008;117:2577-2579.
  10. Диагностика и лечение артериальной гипертензии. Национальные клинические рекомендации. Сборник /Под ред. Р.Г. Оганова. - 2-е издание. - М.: Изд-во «Силицея-Полиграф»,2009. - С292 - 332.
  11. Диагностика и лечение артериальных гипертоний / - Крюков Н.Н., Качковский М.А. Самара: Перспектива, - 2002. - 160с.
  12. Рогоза А.Н. Суточное мониторирование артериального давления //Сердце. - 2002. - Т.1. №5. - С. 240 - 242.
  13. LangR.M., BiergM., DevereuxR.B. etal. Recommendations for chamber quantification. Guidelines // Eur. J. Echocardiography. - 2006. - Vol.7, № 2. - P.79-108.
  14. Guidlines for the managment of arterial hypertension. The Task Force for the Managment of Arterial Hypertension of the European Society of Hypertension (ESH) and European Society of Cardiology (ESC) // Eur. Heart J. - 2007 . - Vol. 28, № 12. - P. 1462 - 1536.



Abstract - 35


Article Metrics

Metrics Loading ...




  • There are currently no refbacks.

Copyright (c) 1970 Kiseleva E.V., Kiseleva E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies